Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin in New Onset Diabetes After Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Newly diagnosed NODAT defined by pathologic OGTT (2h, 75mg glucose): glucose ≥ 200mg/dl~* renal transplantation (deceased or living donor) and treatment with the standard immunosuppression at our center, consisting of triple therapy with tacrolimus or cyclosporine A, mycophenolate mofetil or azathioprine, and prednisone.~* stable graft function for more than 6 months post transplant.~* informed consent of the patient~Exclusion Criteria:~* patients with prior history of type 1 or type 2 diabetes~* body mass index (BMI) \> 40~* pregnancy~* severe renal impairment (GFR \< 30 mL/min./1.73 m2)~* severe liver impairment~* severe blood glucose elevation with the need for therapy with insulin or HbA1c \>8.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin, 50 mg, peroral (Type: ACTIVE_COMPARATOR): None
- Placebo pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).